
| COVID-19, severe asthma, and biologics #MMPMID32553608Garcia-Moguel I; Diaz Campos R; Alonso Charterina S; Fernandez Rodriguez C; Fernandez Crespo JAnn Allergy Asthma Immunol 2020[Sep]; 125 (3): 357-359.e1 PMID32553608show ga
?|Acetates/therapeutic use[MESH]|Adrenergic beta-2 Receptor Antagonists/*therapeutic use[MESH]|Amoxicillin-Potassium Clavulanate Combination/therapeutic use[MESH]|Anti-Asthmatic Agents/*therapeutic use[MESH]|Antibodies, Monoclonal, Humanized/*therapeutic use[MESH]|Asthma/complications/*drug therapy/immunology/virology[MESH]|Azithromycin/therapeutic use[MESH]|Betacoronavirus/immunology/*pathogenicity[MESH]|Budesonide/therapeutic use[MESH]|COVID-19[MESH]|Convalescence[MESH]|Coronavirus Infections/complications/*drug therapy/immunology/virology[MESH]|Cyclopropanes[MESH]|Eosinophils/drug effects/immunology/virology[MESH]|Female[MESH]|Humans[MESH]|Hydroxychloroquine/therapeutic use[MESH]|Ipratropium/therapeutic use[MESH]|Male[MESH]|Middle Aged[MESH]|Pandemics[MESH]|Pneumonia, Viral/complications/*drug therapy/immunology/virology[MESH]|Quinolines/therapeutic use[MESH]|SARS-CoV-2[MESH]|Sulfides[MESH]
  
DeepDyve Pubget Overpricing | 
|